Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Immix Biopharma, Inc. (IMMX)

Immix Biopharma says Richard Graydon no longer with company as of July 17, 2026

Neutral Impact 2 of 5 leadership Written later

Immix Biopharma disclosed that Richard Graydon was terminated and is no longer with the company as of July 17, 2026, for reasons it says are unrelated to his activities at the company. Management believes that, given his short tenure, the departure has no material effect on the business. The filing does not state Graydon's role or give any financial figures.

Key points

  • Termination effective as of July 17, 2026
  • Company says the reasons are unrelated to Graydon's activities at the company
  • Management believes there is no material effect on the business given his short tenure
  • Filing dated July 20, 2026, signed by CEO Ilya Rachman, M.D., Ph.D.

The filing

CompanyImmix Biopharma, Inc. (IMMX)
Form8-K, current report
Filed with the SECJul 20, 2026, 6:05 AM ET
Accession number0001493152-26-033829

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 20, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.